InMed Pharmaceuticals (INM) Enterprise Value (2021 - 2025)
InMed Pharmaceuticals' Enterprise Value history spans 5 years, with the latest figure at -$7.0 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 451.23% year-over-year to -$7.0 million; the TTM value through Dec 2025 reached -$7.0 million, down 451.23%, while the annual FY2025 figure was -$11.1 million, 68.1% down from the prior year.
- Enterprise Value reached -$7.0 million in Q4 2025 per INM's latest filing, up from -$9.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.3 million in Q4 2024 to a low of -$15.4 million in Q3 2021.
- Average Enterprise Value over 5 years is -$7.7 million, with a median of -$6.9 million recorded in 2023.
- Peak YoY movement for Enterprise Value: skyrocketed 88.23% in 2023, then tumbled 451.23% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$11.3 million in 2021, then decreased by 1.5% to -$11.5 million in 2022, then surged by 88.23% to -$1.4 million in 2023, then rose by 5.53% to -$1.3 million in 2024, then crashed by 451.23% to -$7.0 million in 2025.
- Per Business Quant, the three most recent readings for INM's Enterprise Value are -$7.0 million (Q4 2025), -$9.4 million (Q3 2025), and -$11.1 million (Q2 2025).